A phase IIa blinded, multi-center, randomized clinical trial that enrolled 121 patients with stage 3b or 4 CKD has been initiated using the Gal-3 inhibitor GCS100 (registered in Clinical Trial as NCT01843790, Table 1). Here, LGALS3 is linked to chronic kidney disease.